Akums Drugs enters into license and distribution agreement with Triple Hair, Canada

Akums Drugs will undertake this development and commercialization in India

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience

Akums Q1 FY25 revenue up 5.1%

The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually

Akums introduces Hydroxyurea oral suspension for sickle cell disease

This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India

Akums to empower mothers with Doxylamine + Pyridoxine extended-release tablets for severe morning sickness

This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy

Akums acquires new facility in Baddi to enhance tablet manufacturing capacity

his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.

Akums gets approval for triple combination diabetes treatment